11 July 2020 – Itolizumab granted Restricted Emergency Use by DCGI

Type of Intervention: Regulation
Sectors Involved: Health
Intervention Categories: Biological measures; Planning and strategy; Listening to scientists or health/other experts; Research and development
Level of Jurisdiction: National
Lead People/Agency: Drugs Controller General of India; Ministry of Health and Family Welfare

Overview: Based on Phase II clinical trial results generated in COVID-19 patients, the Drugs Controller General of India (DCGI) gives nod for restricted emergency use to Itolizumab for moderate to severe COVID-19 patients.
Full details here: https://pib.gov.in/PressReleasePage.aspx?PRID=1637926

Type of Justification: Advice of INTERNAL government advisory committee or group, Scientific Evidence (e.g. academic paper, report)